SCHEMBL5865233

SCHEMBL5865233

N#Cc1cccc(/C=C/c2ccc(F)cc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 4/20 0.50
NFE2L2 Q16236 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.44
TP53 P04637 1/20 0.42
DHFR P00374 1/20 0.41
NPC1 O15118 1/20 0.40
GRM5 P41594 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865235 1.00 GRM4 (0.50) GRM4NFE2L2ALDH1A1MAPTMEN1
SCHEMBL4712457 0.85 GRM4 (0.56) GRM4ALDH1A1MAPTMEN1KMT2A
SCHEMBL4712459 0.85 GRM4 (0.56) GRM4ALDH1A1MAPTMEN1KMT2A
SCHEMBL5865004 0.84 GRM4 (0.57) GRM4NFE2L2ALDH1A1SMN1; SMN2NPC1
SCHEMBL5865007 0.84 GRM4 (0.57) GRM4NFE2L2ALDH1A1SMN1; SMN2NPC1
SCHEMBL5864800 0.84 NPC1 (0.50) GRM4NFE2L2ALDH1A1MAPTMEN1
SCHEMBL5864968 0.84 KDM4E (0.47) GRM4NFE2L2ALDH1A1MAPTMEN1
SCHEMBL5864794 0.84 NPC1 (0.50) GRM4NFE2L2ALDH1A1MAPTMEN1
SCHEMBL5864973 0.84 KDM4E (0.47) GRM4NFE2L2ALDH1A1MAPTMEN1
SCHEMBL5864866 0.81 MAPT (0.53) NFE2L2MAPTSMN1; SMN2DHFRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034044-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2006-04-25 US disclosed
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER 2006-03-16 US disclosed
US-6951875-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
EP-1443926-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-11 EP disclosed
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER (FR) 2004-04-08 US disclosed
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. 2003-07-31 US disclosed
WO-2003037333-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C GRM4 20/4885NFE2L2 1274/4885ALDH1A1 832/4885
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C GRM4 20/4885NFE2L2 1274/4885ALDH1A1 832/4885
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN3A, GRIN2C GRM4 19/4885NFE2L2 1407/4885ALDH1A1 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.